Phytopharm plc Stock London S.E.
Equities
GB0006869720
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- GBX | - |
|
06-19 | Ixico Bags Over GBP1 Million Contract for Parkinsonian Disorder Study | MT |
06-19 | AIM WINNERS & LOSERS: Ixico and Light Science Technologies win deal | AN |
Sales 2024 * | 5.2M 6.73M 9.22M | Sales 2025 * | - | Capitalization | 3.38M 4.38M 6M |
---|---|---|---|---|---|
Net income 2024 * | -2M -2.59M -3.55M | Net income 2025 * | - | EV / Sales 2024 * | 0.38 x |
Net cash position 2024 * | 1.4M 1.81M 2.48M | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.27
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 51.17% |
Latest transcript on Phytopharm plc
Managers | Title | Age | Since |
---|---|---|---|
Giulio Cerroni
CEO | Chief Executive Officer | 63 | 17-02-05 |
Director of Finance/CFO | 47 | 19-05-30 | |
Charles Spicer
CHM | Chairman | 59 | 13-10-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Charles Spicer
CHM | Chairman | 59 | 13-10-13 |
Director/Board Member | 49 | 16-09-15 | |
Dipti Amin
BRD | Director/Board Member | 60 | 23-10-04 |
1st Jan change | Capi. | |
---|---|---|
+25.19% | 46.56B | |
+45.38% | 41.67B | |
+0.35% | 41.16B | |
+33.30% | 32.4B | |
+21.03% | 28.18B | |
-6.35% | 28.1B | |
+48.97% | 14.52B | |
+47.52% | 13.74B | |
+3.21% | 12.17B |